 Joan Winter
Concepts (119)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpesvirus 4, Human | 5 | 2020 | 172 | 1.930 |
Why?
| | Epstein-Barr Virus Infections | 4 | 2020 | 101 | 1.840 |
Why?
| | Tuberculosis | 4 | 2020 | 284 | 1.450 |
Why?
| | Sheep Diseases | 2 | 2016 | 9 | 0.960 |
Why?
| | Animal Husbandry | 2 | 2016 | 33 | 0.940 |
Why?
| | England | 7 | 2020 | 110 | 0.850 |
Why?
| | Cytomegalovirus Infections | 2 | 2020 | 206 | 0.690 |
Why?
| | Infectious Mononucleosis | 2 | 2020 | 10 | 0.670 |
Why?
| | Peritonsillar Abscess | 1 | 2020 | 4 | 0.650 |
Why?
| | Molecular Epidemiology | 1 | 2020 | 74 | 0.640 |
Why?
| | Herpesvirus Vaccines | 1 | 2020 | 4 | 0.640 |
Why?
| | Cytomegalovirus | 1 | 2020 | 168 | 0.600 |
Why?
| | HIV Infections | 3 | 2020 | 3195 | 0.580 |
Why?
| | Antibodies, Viral | 2 | 2020 | 674 | 0.570 |
Why?
| | Foot Rot | 1 | 2016 | 1 | 0.500 |
Why?
| | Respiratory Tract Infections | 2 | 2020 | 396 | 0.500 |
Why?
| | Coinfection | 1 | 2018 | 143 | 0.490 |
Why?
| | Substance Abuse, Intravenous | 1 | 2017 | 127 | 0.470 |
Why?
| | Anti-Retroviral Agents | 1 | 2018 | 251 | 0.470 |
Why?
| | Lameness, Animal | 1 | 2015 | 27 | 0.450 |
Why?
| | Practice Patterns, Physicians' | 3 | 2020 | 1372 | 0.440 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 644 | 0.390 |
Why?
| | Primary Health Care | 3 | 2020 | 1736 | 0.390 |
Why?
| | Anti-Bacterial Agents | 3 | 2020 | 1925 | 0.390 |
Why?
| | Risk Factors | 7 | 2020 | 10916 | 0.290 |
Why?
| | Northern Ireland | 2 | 2018 | 12 | 0.270 |
Why?
| | Wales | 2 | 2018 | 26 | 0.270 |
Why?
| | Prevalence | 4 | 2019 | 2874 | 0.260 |
Why?
| | Young Adult | 8 | 2020 | 14250 | 0.260 |
Why?
| | Adolescent | 9 | 2020 | 22569 | 0.260 |
Why?
| | United Kingdom | 3 | 2020 | 358 | 0.220 |
Why?
| | Incidence | 3 | 2020 | 2933 | 0.200 |
Why?
| | Sheep | 2 | 2016 | 876 | 0.190 |
Why?
| | Seroepidemiologic Studies | 2 | 2020 | 171 | 0.190 |
Why?
| | Cohort Studies | 4 | 2020 | 6032 | 0.170 |
Why?
| | Female | 10 | 2020 | 79025 | 0.170 |
Why?
| | Vaccination | 2 | 2020 | 1428 | 0.170 |
Why?
| | General Practice | 1 | 2020 | 32 | 0.160 |
Why?
| | Cross-Sectional Studies | 3 | 2020 | 5921 | 0.150 |
Why?
| | Policy | 1 | 2020 | 149 | 0.140 |
Why?
| | Child | 6 | 2020 | 22738 | 0.140 |
Why?
| | Male | 8 | 2020 | 72992 | 0.140 |
Why?
| | Health Surveys | 1 | 2020 | 520 | 0.140 |
Why?
| | Bayes Theorem | 1 | 2020 | 421 | 0.140 |
Why?
| | Carcinoma | 1 | 2020 | 227 | 0.140 |
Why?
| | Life Style | 1 | 2020 | 486 | 0.130 |
Why?
| | Bacterial Infections | 1 | 2020 | 246 | 0.130 |
Why?
| | Antimicrobial Stewardship | 1 | 2020 | 130 | 0.130 |
Why?
| | Dichelobacter nodosus | 1 | 2016 | 1 | 0.130 |
Why?
| | Models, Theoretical | 2 | 2019 | 560 | 0.130 |
Why?
| | Odds Ratio | 1 | 2019 | 1083 | 0.120 |
Why?
| | Humans | 12 | 2020 | 145750 | 0.120 |
Why?
| | Membrane Proteins | 2 | 2014 | 1166 | 0.120 |
Why?
| | Immunoglobulin G | 1 | 2020 | 892 | 0.120 |
Why?
| | Bacterial Typing Techniques | 1 | 2016 | 40 | 0.120 |
Why?
| | Family Practice | 1 | 2020 | 407 | 0.120 |
Why?
| | Decision Support Techniques | 1 | 2020 | 479 | 0.120 |
Why?
| | Vaccines | 1 | 2020 | 389 | 0.110 |
Why?
| | Rod Cell Outer Segment | 1 | 2014 | 4 | 0.110 |
Why?
| | Middle Aged | 5 | 2020 | 36297 | 0.110 |
Why?
| | Rhodopsin | 1 | 2014 | 11 | 0.110 |
Why?
| | Sex Factors | 1 | 2020 | 2110 | 0.100 |
Why?
| | Logistic Models | 1 | 2019 | 2139 | 0.100 |
Why?
| | Sepsis | 1 | 2020 | 664 | 0.100 |
Why?
| | Adult | 5 | 2020 | 40867 | 0.100 |
Why?
| | Age Factors | 1 | 2020 | 3346 | 0.090 |
Why?
| | Seasons | 1 | 2015 | 538 | 0.090 |
Why?
| | Mycobacterium tuberculosis | 1 | 2016 | 318 | 0.090 |
Why?
| | GTP-Binding Protein beta Subunits | 1 | 2011 | 17 | 0.090 |
Why?
| | Intracellular Fluid | 1 | 2011 | 25 | 0.090 |
Why?
| | RGS Proteins | 1 | 2011 | 17 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2933 | 0.090 |
Why?
| | Aged, 80 and over | 3 | 2020 | 8346 | 0.090 |
Why?
| | Photoreceptor Cells, Vertebrate | 1 | 2011 | 29 | 0.090 |
Why?
| | Aged | 4 | 2020 | 26212 | 0.080 |
Why?
| | Retrospective Studies | 2 | 2020 | 17322 | 0.080 |
Why?
| | Proteolysis | 1 | 2011 | 172 | 0.080 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 1430 | 0.070 |
Why?
| | Retina | 1 | 2011 | 329 | 0.070 |
Why?
| | Neoplasms | 2 | 2020 | 2913 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 6084 | 0.060 |
Why?
| | Animals | 4 | 2016 | 38100 | 0.060 |
Why?
| | Infant, Newborn | 3 | 2020 | 6464 | 0.050 |
Why?
| | Infant | 3 | 2020 | 10089 | 0.040 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2020 | 21 | 0.040 |
Why?
| | Child, Preschool | 3 | 2020 | 11866 | 0.040 |
Why?
| | Burkitt Lymphoma | 1 | 2020 | 61 | 0.040 |
Why?
| | Probability | 1 | 2020 | 308 | 0.040 |
Why?
| | Frail Elderly | 1 | 2020 | 136 | 0.040 |
Why?
| | Drug Utilization | 1 | 2020 | 168 | 0.040 |
Why?
| | Calibration | 1 | 2019 | 152 | 0.040 |
Why?
| | Stomach Neoplasms | 1 | 2020 | 128 | 0.030 |
Why?
| | Hodgkin Disease | 1 | 2020 | 172 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2020 | 288 | 0.030 |
Why?
| | Urinary Tract Infections | 1 | 2020 | 210 | 0.030 |
Why?
| | Signal Transduction | 1 | 2011 | 5223 | 0.030 |
Why?
| | Frailty | 1 | 2020 | 205 | 0.030 |
Why?
| | Genome, Bacterial | 1 | 2016 | 123 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2020 | 868 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2014 | 219 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 778 | 0.020 |
Why?
| | Protein Transport | 1 | 2014 | 442 | 0.020 |
Why?
| | Recurrence | 1 | 2016 | 1139 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2014 | 855 | 0.020 |
Why?
| | Dark Adaptation | 1 | 2011 | 13 | 0.020 |
Why?
| | Mice, Inbred C57BL | 2 | 2014 | 5992 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2020 | 1202 | 0.020 |
Why?
| | SNARE Proteins | 1 | 2011 | 41 | 0.020 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2011 | 141 | 0.020 |
Why?
| | Electroporation | 1 | 2011 | 43 | 0.020 |
Why?
| | Genetic Variation | 1 | 2016 | 976 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5428 | 0.020 |
Why?
| | Light | 1 | 2011 | 403 | 0.020 |
Why?
| | Cell Membrane | 1 | 2011 | 709 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 3130 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2011 | 2191 | 0.010 |
Why?
| | Mice | 2 | 2014 | 18357 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2601 | 0.010 |
Why?
| | Mutation | 1 | 2011 | 4090 | 0.010 |
Why?
|
|
Winter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|